Cargando…

F22. DYSLIPIDEMIA AND INFLAMMATORY MARKERS IN RELATION TO CLINICAL SYMPTOMATOLOGY IN PSYCHOTIC DISORDERS

BACKGROUND: Although the role of lipid disturbances and inflammation in psychotic disorders have been demonstrated in a substantial body of research, the association between clinical symptomatology and these two important pathways has not been studied in detail. The main aim of this study was to inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Gohar, Sherif M, Dieset, Ingrid, Steen, Nils Eiel, Mørch, Ragni H, Iversen, Trude S, Steen, Vidar M, Andreassen, Ole A, Melle, Ingrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888170/
http://dx.doi.org/10.1093/schbul/sby017.553
_version_ 1783312462736523264
author Gohar, Sherif M
Dieset, Ingrid
Steen, Nils Eiel
Mørch, Ragni H
Iversen, Trude S
Steen, Vidar M
Andreassen, Ole A
Melle, Ingrid
author_facet Gohar, Sherif M
Dieset, Ingrid
Steen, Nils Eiel
Mørch, Ragni H
Iversen, Trude S
Steen, Vidar M
Andreassen, Ole A
Melle, Ingrid
author_sort Gohar, Sherif M
collection PubMed
description BACKGROUND: Although the role of lipid disturbances and inflammation in psychotic disorders have been demonstrated in a substantial body of research, the association between clinical symptomatology and these two important pathways has not been studied in detail. The main aim of this study was to investigate the associations between serum lipid levels [total cholesterol (TC), low density lipoprotein (LDL), triglyceride (TG)]; general or specific inflammatory markers [C-reactive protein (CRP), soluble tumor necrosis factor receptor 1(sTNF-R1), osteoprotegerin (OPG), interleukin 1 receptor antagonist (IL-1Ra)]; and clinical symptoms (positive, negative and depressive) in patients with psychotic disorders. METHODS: The sample is consisted of 652 participants divided in two groups: Schizophrenia, schizophreniform and schizoaffective, (schizophrenia group, N = 344); psychosis NOS, psychotic bipolar I, II and NOS, (non-schizophrenia group, N = 308) recruited consecutively between 2003 and 2015 from five major hospitals in Oslo, Norway, as part of Thematically Organized Psychosis (TOP) Study. The Regional Committee for Medical Research Ethics approved the study. Demographic, clinical and medications data were obtained by clinical interviews and from medical records. SCID-I was used for diagnosis in addition to Positive and Negative Syndrome Scale (PANSS) and Calgary Depression Scale for Schizophrenia (CDSS) to assess symptoms severity. Bivariate and multivariate analyses were performed to evaluate associations between symptom profiles, lipid levels and inflammatory markers. RESULTS: Schizophrenia group showed higher levels of TC and LDL compared to non-schizophrenia group after adjusting for age, gender, BMI, smoking, and medications. TC and LDL were positively correlated with depression, whereas TG and LDL were positively correlated with negative symptoms. CRP and OPG were significantly associated with higher levels of TC and LDL. While, sTNF-R1 showed significant positive correlation only with TG. In multivariate regression, higher LDL was significantly associated with higher age, BMI, depressive severity in addition to two inflammatory markers CRP and OPG. DISCUSSION: The findings of this study highlight the importance of understanding the interaction between inflammatory markers and lipid, and their relation to clinical profile especially depression in psychotic disorders
format Online
Article
Text
id pubmed-5888170
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-58881702018-04-11 F22. DYSLIPIDEMIA AND INFLAMMATORY MARKERS IN RELATION TO CLINICAL SYMPTOMATOLOGY IN PSYCHOTIC DISORDERS Gohar, Sherif M Dieset, Ingrid Steen, Nils Eiel Mørch, Ragni H Iversen, Trude S Steen, Vidar M Andreassen, Ole A Melle, Ingrid Schizophr Bull Abstracts BACKGROUND: Although the role of lipid disturbances and inflammation in psychotic disorders have been demonstrated in a substantial body of research, the association between clinical symptomatology and these two important pathways has not been studied in detail. The main aim of this study was to investigate the associations between serum lipid levels [total cholesterol (TC), low density lipoprotein (LDL), triglyceride (TG)]; general or specific inflammatory markers [C-reactive protein (CRP), soluble tumor necrosis factor receptor 1(sTNF-R1), osteoprotegerin (OPG), interleukin 1 receptor antagonist (IL-1Ra)]; and clinical symptoms (positive, negative and depressive) in patients with psychotic disorders. METHODS: The sample is consisted of 652 participants divided in two groups: Schizophrenia, schizophreniform and schizoaffective, (schizophrenia group, N = 344); psychosis NOS, psychotic bipolar I, II and NOS, (non-schizophrenia group, N = 308) recruited consecutively between 2003 and 2015 from five major hospitals in Oslo, Norway, as part of Thematically Organized Psychosis (TOP) Study. The Regional Committee for Medical Research Ethics approved the study. Demographic, clinical and medications data were obtained by clinical interviews and from medical records. SCID-I was used for diagnosis in addition to Positive and Negative Syndrome Scale (PANSS) and Calgary Depression Scale for Schizophrenia (CDSS) to assess symptoms severity. Bivariate and multivariate analyses were performed to evaluate associations between symptom profiles, lipid levels and inflammatory markers. RESULTS: Schizophrenia group showed higher levels of TC and LDL compared to non-schizophrenia group after adjusting for age, gender, BMI, smoking, and medications. TC and LDL were positively correlated with depression, whereas TG and LDL were positively correlated with negative symptoms. CRP and OPG were significantly associated with higher levels of TC and LDL. While, sTNF-R1 showed significant positive correlation only with TG. In multivariate regression, higher LDL was significantly associated with higher age, BMI, depressive severity in addition to two inflammatory markers CRP and OPG. DISCUSSION: The findings of this study highlight the importance of understanding the interaction between inflammatory markers and lipid, and their relation to clinical profile especially depression in psychotic disorders Oxford University Press 2018-04 2018-04-01 /pmc/articles/PMC5888170/ http://dx.doi.org/10.1093/schbul/sby017.553 Text en © Maryland Psychiatric Research Center 2018. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstracts
Gohar, Sherif M
Dieset, Ingrid
Steen, Nils Eiel
Mørch, Ragni H
Iversen, Trude S
Steen, Vidar M
Andreassen, Ole A
Melle, Ingrid
F22. DYSLIPIDEMIA AND INFLAMMATORY MARKERS IN RELATION TO CLINICAL SYMPTOMATOLOGY IN PSYCHOTIC DISORDERS
title F22. DYSLIPIDEMIA AND INFLAMMATORY MARKERS IN RELATION TO CLINICAL SYMPTOMATOLOGY IN PSYCHOTIC DISORDERS
title_full F22. DYSLIPIDEMIA AND INFLAMMATORY MARKERS IN RELATION TO CLINICAL SYMPTOMATOLOGY IN PSYCHOTIC DISORDERS
title_fullStr F22. DYSLIPIDEMIA AND INFLAMMATORY MARKERS IN RELATION TO CLINICAL SYMPTOMATOLOGY IN PSYCHOTIC DISORDERS
title_full_unstemmed F22. DYSLIPIDEMIA AND INFLAMMATORY MARKERS IN RELATION TO CLINICAL SYMPTOMATOLOGY IN PSYCHOTIC DISORDERS
title_short F22. DYSLIPIDEMIA AND INFLAMMATORY MARKERS IN RELATION TO CLINICAL SYMPTOMATOLOGY IN PSYCHOTIC DISORDERS
title_sort f22. dyslipidemia and inflammatory markers in relation to clinical symptomatology in psychotic disorders
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888170/
http://dx.doi.org/10.1093/schbul/sby017.553
work_keys_str_mv AT goharsherifm f22dyslipidemiaandinflammatorymarkersinrelationtoclinicalsymptomatologyinpsychoticdisorders
AT diesetingrid f22dyslipidemiaandinflammatorymarkersinrelationtoclinicalsymptomatologyinpsychoticdisorders
AT steennilseiel f22dyslipidemiaandinflammatorymarkersinrelationtoclinicalsymptomatologyinpsychoticdisorders
AT mørchragnih f22dyslipidemiaandinflammatorymarkersinrelationtoclinicalsymptomatologyinpsychoticdisorders
AT iversentrudes f22dyslipidemiaandinflammatorymarkersinrelationtoclinicalsymptomatologyinpsychoticdisorders
AT steenvidarm f22dyslipidemiaandinflammatorymarkersinrelationtoclinicalsymptomatologyinpsychoticdisorders
AT andreassenolea f22dyslipidemiaandinflammatorymarkersinrelationtoclinicalsymptomatologyinpsychoticdisorders
AT melleingrid f22dyslipidemiaandinflammatorymarkersinrelationtoclinicalsymptomatologyinpsychoticdisorders